Clinical trial
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer…
NCT00056407 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00056407 |
|---|---|
| Title | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer |
| Acronym | REDUCE |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Prostate |
| Intervention type | Drug |
| Interventions | Dutasteride, Placebo |
| Enrollment | 8,231 |
| Start date | Mar 1, 2003 |
| Primary completion | Jan 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Mar 13, 2003 |
| Last update posted | Sep 23, 2016 |
| Countries | Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, Croatia, Denmark, Estonia and 30 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: